Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2937

Sort by

Sort Order Select

Journal Articles

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Mounica Vallurupalli, Nancy Berliner

Blood (2019) 134 (21): 1783–1786.

https://doi.org/10.1182/blood.2019002289

Published: 2019

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Impact of Cytoreductive Therapy and Depth of Response before Allogeneic Transplantation for Advanced Myelodysplastic Syndrome

Yu Wang, Lan-Ping Xu, Kaiyan Liu, MD PhD, Xiao-Hui Zhang, Chen-hua Yan, Xiao-Jun Huang, MD

Blood (2019) 134 (Supplement_1): 4607.

https://doi.org/10.1182/blood-2019-124046

Published: 2019

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

Rémy Duléry, MD, Laure Lebras, MD, Sylvain Choquet, MD, Roberta Di Blasi, Ahmad Kanj AL Jijakli, Laurence Heuberger, Eolia Brissot, MD PhD, Giorgia Battipaglia, MD, Florent Malard, MD PhD, Clemence Mediavilla, MD, Anne Vekhoff, MD, Paul Coppo, MD PhD, Tounes Ledraa, MD, Zora Marjanovic, Elise Corre, MD, Simona Lapusan, MD, Malek Aoudjhane, MD, Ramdane Belhocine, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 786.

https://doi.org/10.1182/blood-2019-130651

Published: 2019

Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes

Blood (2019) 134 (Supplement_1): 1523.

https://doi.org/10.1182/blood-2019-123908

Published: 2019

Journal Articles

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Blood (2019) 134 (Supplement_1): 1554.

https://doi.org/10.1182/blood-2019-129199

Published: 2019

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

https://doi.org/10.1182/blood-2019-127881

Published: 2019

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib

Blood (2019) 134 (Supplement_1): 1503.

https://doi.org/10.1182/blood-2019-126459

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD

Blood (2019) 134 (Supplement_1): 1547.

https://doi.org/10.1182/blood-2019-124351

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Mary Jo Lechowicz, MD, Dolores Caballero, MD PhD, Mollie Leoni, MD, Marilyn Tabachri, RN, BSN, Fiona Herr, PhD, Zanetta S. Lamar, MD

Blood (2019) 134 (Supplement_1): 5297.

https://doi.org/10.1182/blood-2019-129302

Published: 2019

Journal Articles

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Ruetima Titapiwatanakun, MD, Sukhjeet Singh Batth, MD, Katherine Baker, NP, Wendy Tcheng, MD, Karen S. Fernandez, MD

Blood (2019) 134 (Supplement_1): 5298.

https://doi.org/10.1182/blood-2019-122973

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Myrna Candelaria, MD PharmD, Adriana Palacios Campos, MD, Olga Gutierrez Hernandez, QFB, Alejandro Aviles, MD, Uvi Cancino-Ramos, MD, Lucia Taja Chayeb, PhD, Osvaldo García-Perez, MD, David Cantú de León

Blood (2019) 134 (Supplement_1): 5222.

https://doi.org/10.1182/blood-2019-125906

Published: 2019

Journal Articles

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Jayant Narang, MD, Surabhi Bajpai, MD, Rudresh Rajnikant Jarecha, MBBS, MD, Sayali Karve, PhD, Katarina Ludajic, PhD, Manish Sharma, MD, Shweta Narang, MD, Michael O'Connor, PhD

Blood (2019) 134 (Supplement_1): 5277.

https://doi.org/10.1182/blood-2019-130570

Published: 2019

NARROW

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Impact of Cytoreductive Therapy and Depth of Response before Allogeneic Transplantation for Advanced Myelodysplastic Syndrome

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only